Study of the Effect of Hydrocortisone Administered for the Prevention of Pulmonary Bronchodysplasia (PREMILOC Trial) on the Determinants of Systemic Blood Pressure in Children (PREMILOCAP)

The requested reference [9954b2d66af87d1d613f77a3e4fb7b433d3a3af9] no longer exists in our database. It has been replaced by the current reference: [80e8966b59ae29e096012faf2520f210fce22764]

Authors Assistance Publique - Hôpitaux de Paris -More
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
Links ClinicalTrials.gov
The risk of Arterial Hypertension (HTA) is increased in very premature infants and hydrocortisone administered in the neonatal period could modify this risk. The main objective is to assess whether the administration of hydrocortisone in the perinatal period in children born prematurely is associated with an increase in Pulse Wave Velocity (PWV) by comparing the future of children included in the PREMILOC trial (hydrocortisone versus placebo) at the age of 7-13 years. The primary endpoint will be the carotid-femoral pulse wave velocity in m/s.
Epistemonikos ID: a23919b9facfb842a10d645ae250b83fb7de166f
First added on: May 13, 2024